Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review)

  • Authors:
    • Zhiyou Cai
  • View Affiliations

  • Published online on: March 11, 2014     https://doi.org/10.3892/mmr.2014.2040
  • Pages: 1533-1541
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Activated monoamine oxidase (MAO) has a critical role in the pathogenesis of Alzheimer's disease (AD), including the formation of amyloid plaques from amyloid β peptide (Aβ) production and accumulation, formation of neurofibrillary tangles, and cognitive impairment via the destruction of cholinergic neurons and disorder of the cholinergic system. Several studies have indicated that MAO inhibitors improve cognitive deficits and reverse Aβ pathology by modulating proteolytic cleavage of amyloid precursor protein and decreasing Aβ protein fragments. Thus, MAO inhibitors may be considered as promising therapeutic agents for AD.
View Figures
View References

Related Articles

Journal Cover

May 2014
Volume 9 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Cai, Z. (2014). Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review). Molecular Medicine Reports, 9, 1533-1541. https://doi.org/10.3892/mmr.2014.2040
MLA
Cai, Z."Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review)". Molecular Medicine Reports 9.5 (2014): 1533-1541.
Chicago
Cai, Z."Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review)". Molecular Medicine Reports 9, no. 5 (2014): 1533-1541. https://doi.org/10.3892/mmr.2014.2040